Augustine Therapeutics awarded EUR 1.2 million VLAIO research grant to
develop new medicines for neuromuscular diseases
Leuven, Belgium, 23rd March 2021 - Augustine Therapeutics, a biotech spin-out company from VIB that focuses on the development of novel innovative therapies for rare peripheral neuropathies and neurogenerative disorders, has received EUR 1.2 million in funding from the Flanders Agency for Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new medicines for peripheral neuropathies through innovative research by elucidating the mode of action of second-generation selective HDAC6 inhibitors developed by Augustine Therapeutics
Therapeutics for neuromuscular diseases
Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular diseases. The newly formed company is rooted in the ground-breaking research at VIB and KU Leuven and supported by V-Bio Ventures, PMV, Advent France Biotechnology and Gemma Frisius Fund.